Ann Dermatol.  2018 Oct;30(5):614-616. 10.5021/ad.2018.30.5.614.

Pirfenidone-Induced Photosensitivity in a Patient with Idiopathic Pulmonary Fibrosis

• Kim HJ
• Seo JW
• Kim TH
• Choi SH
• Song KH
• Kim KH

• KMID: 2419756
• DOI: http://doi.org/10.5021/ad.2018.30.5.614

Abstract

No abstract available.

MeSH Terms

Humans
Idiopathic Pulmonary Fibrosis*

Figure

• 

  Fig. 1 Multiple erythematous scaly patches and plaques on the anterior neck (A) and both forearms (B, C). Six weeks after the discontinuation of pirfenidone, multiple well demarcated hyperpigmented macules on the anterior neck (D) and both forearms (E, F).

• 

  Fig. 2 A photosensitivity test showed a markedly decreased minimum erythema dose (MED) of 2 J/cm2 with ultraviolet A (UV-A) (A) and 28 mJ/cm2 with ultraviolet B (UV-B) (B). Six weeks after the discontinuation of pirfenidone, irradiation with 15 J/cm2 of UV-A induced no erythema (C) and UV-B MED remained at 28 mJ/cm2 (D).

Reference

1. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377:1760–1769.

2. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 35:821–829.

3. Seto Y, Inoue R, Kato M, Yamada S, Onoue S. Photosafety assessments on pirfenidone: photochemical, photobiological, and pharmacokinetic characterization. J Photochem Photobiol B. 2013; 120:44–51.

4. Son YM, Roh JY, Cho EK, Lee JR. Photosensitivity reactions to vandetanib: redevelopment after sequential treatment with docetaxel. Ann Dermatol. 2011; 23:Suppl 3. S314–S318.

5. Tsuruta A, Washio K, Fukunaga A, Nishigori C. Pirfenidone-induced photoleukomelanoderma in a patient with idiopathic pulmonary fibrosis. J Dermatol. 2016; 43:207–209.